UroGen Pharma director granted RSUs and stock options

UroGen Pharma director Daniel George Wildman received new equity awards.

Rhea-AI Filing Summary

UroGen Pharma director Daniel George Wildman received new equity awards. He was granted 8,000 restricted stock units and stock options for 10,000 ordinary shares at an exercise price of $34.99 per share. Both the RSUs and options vest in equal quarterly installments over one year, contingent on his continuous service.

Insider Trade Summary

Grant/Award: 18,000 shares

Grant/Award 2 txns

Insider Wildman Daniel George

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right ot buy)	10,000	$0.00	$0.00
Grant/Award	Restricted Stock Unit	8,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right ot buy) — 10,000 contracts (Direct); Restricted Stock Unit — 8,000 contracts (Direct)

Footnotes (3)

1. F1. The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
2. F2. Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
3. F3. The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.

Key Figures

RSU grant size: 8,000 units Stock option grant size: 10,000 options Option exercise price: $34.99 per share +3 more

6 metrics

RSU grant size 8,000 units Restricted Stock Units granted to director on June 22, 2026

Stock option grant size 10,000 options Options on ordinary shares granted to director on June 22, 2026

Option exercise price $34.99 per share Conversion/exercise price for stock options expiring June 22, 2036

Option expiration date June 22, 2036 Final expiration for director stock option grant

RSUs underlying shares 8,000 shares Each RSU represents one ordinary share, contingent on vesting

Options underlying shares 10,000 shares Stock options relate to 10,000 ordinary shares of the issuer

Key Terms

Restricted Stock Unit, Stock Option, Continuous Service, 2017 Equity Incentive Plan

4 terms

Restricted Stock Unit financial

"security_title: "Restricted Stock Unit" for 8,000.0000 granted on June 22, 2026"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Stock Option financial

"security_title: "Stock Option (right ot buy)" for 10,000.0000 shares"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Continuous Service financial

"will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service"

2017 Equity Incentive Plan financial

"Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did UroGen Pharma (URGN) director Daniel George Wildman receive?

Daniel George Wildman received 8,000 restricted stock units and options for 10,000 ordinary shares. The options carry an exercise price of $34.99 per share, providing additional long-term equity-based compensation linked to UroGen Pharma’s share performance.

How do the new UroGen Pharma (URGN) RSU awards for director Wildman vest?

The 8,000 restricted stock units vest in equal quarterly installments over one year. Vesting is conditioned on the director’s Continuous Service under UroGen Pharma’s 2017 Equity Incentive Plan throughout each scheduled vesting date.

What are the terms of Daniel Wildman’s new UroGen Pharma (URGN) stock options?

Wildman received options on 10,000 ordinary shares with a $34.99 exercise price. These options vest in equal quarterly installments over one year and expire on June 22, 2036, assuming he maintains Continuous Service during the vesting period.

Does this UroGen Pharma (URGN) Form 4 show open-market buying or selling by the director?

No open-market buying or selling is reported. The Form 4 records equity awards classified as grants or awards, including restricted stock units and stock options, rather than discretionary purchases or sales in the market.

What does each UroGen Pharma (URGN) restricted stock unit represent in this filing?

Each restricted stock unit represents a contingent right to receive one ordinary share of UroGen Pharma. Actual share delivery depends on satisfying the vesting schedule and the director maintaining Continuous Service under the company’s 2017 Equity Incentive Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2026 - 10:03 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wildman Daniel George

(Last) (First) (Middle)

400 ALEXANDER PARK DRIVE

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UroGen Pharma Ltd. [ URGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right ot buy)	$34.99	06/22/2026		A		10,000		(1)	06/22/2036	Ordinary Shares	10,000	$0	10,000	D
Restricted Stock Unit	(2)	06/22/2026		A		8,000		(3)	(3)	Ordinary Shares	8,000	$0	8,000	D

Explanation of Responses:

1. The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

3. The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.

	/s/ Jason D. Smith, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)